Emory University

Jon Serody, M.D.

I received my PhD in Immunology and Molecular Pathogenesis from Emory University in Atlanta, GA. While at Emory, I trained in the Department of Surgery at the Emory Transplant Center under Dr. Mandy L. Ford. My thesis work contributed to basic and translational aspects to understand transplant biology and immune tolerance to allografts, where I helped to identify the mechanism(s) by which selective CD28 blockade alters donor-reactive T cell programming by shifting the balance of costimulatory and coinhibitory molecule expression. My dissertation work was supported by a Ruth L. Kirschstein National Research Service Award from the NIAID. I am now a member of Jonathan Serody’s lab at the Lineberger Comprehensive Cancer Center, where I am studying the role of type II innate lymphoid cells (ILC2s) in the lower gastrointestinal tract in graft-versus-host-disease following hematopoietic stem cell transplantation. Specifically, my work uses ChiP-, ATAC-, and FAIRE-sequencing to determine how inflammatory cytokines alter the epigenetic plasticity of ILC2s. As a SPIRE postdoctoral scholar, I am excited to expand my education portfolio, and would like to develop a career in undergraduate teaching and research at a minority-serving institution. I am interested in education research and would like to integrate undergraduate, graduate, post-doctoral, and faculty level experiences to improve mentorship and career outcomes. I believe that it is only through broadening experiences in scientific training, and expanding the training pool to include diversity in race, ethnicity, gender, and sexual orientation will we produce the next-generation of productive researchers that will enhance the research capacity of the United States.

Fall 2020 Special Topics in Immunology – Johnson C. Smith University Spring 2020 Introduction to Biology I – Johnson C. Smith University

Vincent BG- File DM- McKinnon KP- Moore DT- Frelinger JA- Collins EJ- Ibrahim JG- Bixby L- Reisdorf S- Laurie SJ- Park YA- Anders CK- Collichio FA- Muss HB- Carey LA- van Deventer HW- Dees EC- Serody JS. Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors. Journal of immunology (Baltimore- Md. : 1950). 2023 May 19;. PMID: 37204246. 

Anders CK- Woodcock MG- Van Swearingen AED- Moore DT- Sambade MJ- Laurie S- Robeson A- Kolupaev O- Cuaboy LA- Garrett AL- McKinnon K- Cowens K- Bortone D- Calhoun BC- Wilkinson AD- Carey L- Jolly T- Muss H- Reeder-Hayes K- Kaltman R- Jankowitz R- Gudena V- Olajide O- Perou C- Dees EC- Vincent BG- Serody JS. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.. Journal for immunotherapy of cancer. 2022 Feb;10(2). 10.1136/jitc-2021-003427. 35121644. . 

Bruce DW, Kolupaev O, Laurie SJ, Bommiasamy H, Stefanski H, Blazar BR, Coghill JM, Serody JS. Third-party type 2 innate lymphoid cells prevent and treat GI tract GvHD. Blood Adv. 2021 Nov 23;5(22):4578-4589. PMCID: PMC8759141.

Xu N- Palmer DC- Robeson AC- Shou P- Bommiasamy H- Laurie SJ– Willis C- Dotti G- Vincent BG- Restifo NP- Serody JS. STING agonist promotes CAR T cell trafficking and persistence in breast cancer.. The Journal of experimental medicine. 2021 Feb 1;218(2). 10.1084/jem.20200844. 33382402. pmc-id: PMC7780733